Journal
CURRENT MOLECULAR PHARMACOLOGY
Volume 13, Issue 4, Pages 261-272Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1874467213666200224102820
Keywords
Hepatocellular carcinoma; fibrosis; hepatic stellate cell; molecular targets; therapeutics; biomarkers
Funding
- National Natural Science Foundation [81702419]
- Jiangsu Graduate innovation [KYCX17_1934]
- Nantong Science and Technology Project [MS12019013]
Ask authors/readers for more resources
Liver cancer is a leading cause of cancer-related death worldwide, in which hepatocellular carcinoma (HCC) accounts for the majority. Despite the progression in treatment, the prognosis remains extremely poor for HCC patients. The mechanisms of hepatocarcinogenesis are complex, of which fibrosis is acknowledged as the pre-cancerous stage of HCC. Approximately, 80-90% of HCC develops in the fibrotic or cirrhotic livers. Hepatic stellate cells (HSCs), the main effector cells of liver fibrosis, could secret various biological contents to maintain the liver inflammation. By decades, HSCs are increasingly correlated with HCC in the tumor microenvironment. In this review, we summarized the underlying mechanisms that HSCs participated in the genesis and progression of HCC. HSCs secrete various bioactive contents and regulate tumor-related pathways, subsequently contribute to metastasis, angiogenesis, immunosuppression, chemoresistance and cancer stemness. The study indicates that HSC plays vital roles in HCC progression, suggesting it as a promising therapeutic target for HCC treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available